A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MSKCC / Memorial Sloan-Kettering Cancer Center

[Related PubMed/MEDLINE]
Total Number of Papers: 596
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MSKCC  (>> Co-occurring Abbreviation)
Long Form:   Memorial Sloan-Kettering Cancer Center
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2023 Demographics, Pattern of Care & Outcomes of Primary CNS Lymphoma- Experience from a Tertiary Care Cancer Center in India. ACST, ECOG, HD-MTX, IELSG, OS, PCNSL, PFS, PS, WBRT
2023 Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study. OS, RCC, SRCC, TKI
2023 Representativeness of initial skin biopsies showing pure desmoplastic melanoma: implications for management. DM, MDM, MIA, PDM, SLNB
2022 "Long-term outcome in endometrial cancer patients after robot-assisted laparoscopic surgery with sentinel lymph node mapping". SLN
2022 A New Model for Predicting Nonsentinel Lymph Node Metastasis in Early-Stage Breast Cancer Using MMP15. ALND, BC, MMP15, NSLN, ROC, SLNs
2022 A Novel Microbiome Signature in Gastric Cancer: A Two Independent Cohort Retrospective Analysis. GC
2022 Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. DFCI, NSCLC, ORR, OS, PD-1, PD-L1, PFS, TMB
2022 Attention-based Deep Learning for the Preoperative Differentiation of Axillary Lymph Node Metastasis in Breast Cancer on DCE-MRI. ALN, AUC, DCE-MRI, DL, ResNet
2022 CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment. GSEA, ICIs, TMB
10  2022 Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma. CDC, IMDC
11  2022 Clinicopathological characteristics, survival outcomes, and genetic alterations of younger patients with gastric cancer: Results from the China National Cancer Center and cBioPortal datasets. GC, NCCGCDB, OS
12  2022 Comprehensive Analysis of Cell Cycle-Related Genes in Patients With Prostate Cancer. CCRGs, GSVA, HPA, KM, RFS
13  2022 Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patients. DCAs, NCCN, PCa, PSA, SEER, SVI
14  2022 Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer. CI, EGFR-mutant, EGFR-TKIs, HR, ICIs, KRAS, NSCLC, PFS
15  2022 Diagnostic Accuracy of Contemporary Selection Criteria in Prostate Cancer Patients Eligible for Active Surveillance: A Bayesian Network Meta-Analysis. AS, DOR, EC, NMA, PRIAS, UCSF, UM, UT
16  2022 Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma. DFS, DR, DSD, LR, OS, RPS
17  2022 External validation of the MSKCC nomogram to estimate five-year overall survival after surgery for stage I-III colon cancer in a Dutch population. NCR, OS
18  2022 Family as a Bridge to Improve Meaning in Latinx Individuals Coping with Cancer. LMC, PHSU
19  2022 First person profile: Monica Morrow, MD: The chief of the Breast Service at Memorial Sloan Kettering Cancer Center (MSKCC) has made a lasting impact on breast surgical oncology: The chief of the Breast Service at Memorial Sloan Kettering Cancer Center (MSKCC) has made a lasting impact on breast surgical oncology. ---
20  2022 First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis. aRCC, ICERs, IMDC, LP, LYs, QALYs, US
21  2022 Genomic and clinicopathological features of lung adenocarcinomas with micropapillary component. LA
22  2022 Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions. ALK, CNVs, NGS, NTRK, PD-L1, ROS1, RTK
23  2022 High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations. CRC, OS, TMB
24  2022 Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC. GMS, ICI, NSCLC, OS, PFS
25  2022 Identification and validation of an E2F-related gene signature for predicting recurrence-free survival in human prostate cancer. GSVA, PCa, RFS, ROC, TCGA-PRAD
26  2022 Identification ofISG15 and ZFP36 as novel hypoxia- and immune-related gene signatures contributing to a new perspective for the treatment of prostate cancer by bioinformatics and experimental verification. PCa, WB
27  2022 Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. BM, DFS, NAC, OS, pCR
28  2022 Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas. BCs, HLBCs
29  2022 Integrin Expression in Localized Prostate Cancer: A TCGA and MSKCC Cohort-based Exploratory In Silico Analysis. AJCC, DFS, ISUP, ITG, PC
30  2022 Intratumoral and peritumoral radiomics for preoperatively predicting the axillary non-sentinel lymph node metastasis in breast cancer on the basis of contrast-enhanced mammography: a multicenter study. AUC, CEM, CI, NSLN, ROIs
31  2022 Lack of complete response pretransplant is not associated with inferior overall survival for stage 4a metastatic retinoblastoma. CR, IFRT, OS, PR, Rb, VGPR
32  2022 Machine Learning-Based Epigenetic Classifiers for Axillary Staging of Patients with ER-Positive Early-Stage Breast Cancer. AUC, DMS, DNAm, EBC, ER, MDACC
33  2022 MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer. DDR, ICIs, MED12, MED12-Mut, MED12-Wt, WES
34  2022 Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry. ---
35  2022 mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers. ICI, TMB
36  2022 Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non-small cell lung cancer. DDR, EAp53, NSCLC, OS
37  2022 Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB. MT, NSCLC, OS, PFS, WT
38  2022 Predictive Value of Cribriform and Intraductal Carcinoma for the Nomogram-based Selection of Prostate Cancer Patients for Pelvic Lymph Node Dissection. AUC, LNM, PCa
39  2022 Preoperative prediction of pelvic lymph nodes metastasis in prostate cancer using an ADC-based radiomics model: comparison with clinical nomograms and PI-RADS assessment. AUC, DCA, ePLND, PCa, PLNM, RP
40  2022 Preoperative predictive factors affecting sentinel lymph node positivity in breast cancer and comparison of their effectiveness with existing nomograms. ESBC, HER2, LVI, MDACC, ROC, SLN
41  2022 Proposed new prognostic model using the systemic immune-inflammation index for primary central nervous system lymphoma: A prospective-retrospective multicohort analysis. OS, PCNSL, PFS, SII
42  2022 The long-term evolution of melanocytic nevi among high-risk adults. TBP
43  2022 Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients. CI, CMV, HSCT, OS, TCD
44  2022 [Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma]. ICI, TMB
45  2021 A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay. DCIS, IBE
46  2021 A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups. dNLR, ECOG PS, NHL, NLR, OS, PCNSL, ROC
47  2021 Aesthetic forehead reduction in female patients: Surgical details and analysis of outcome. ---
48  2021 An independent assessment of an artificial intelligence system for prostate cancer detection shows strong diagnostic accuracy. WSIs
49  2021 Analysis of the EGFR Amplification and CDKN2A Deletion Regulated Transcriptomic Signatures Reveals the Prognostic Significance of SPATS2L in Patients With Glioma. CGGA, EGFR, GBM, LGG, SPATS2L
50  2021 Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database. C-index, SEER
51  2021 Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy. APL, ATO, ATRA
52  2021 Association of MUC19 Mutation With Clinical Benefits of Anti-PD-1 Inhibitors in Non-small Cell Lung Cancer. DCB, ECOG, NSCLC, PFS, TME, WES
53  2021 Cardiac radiation-induced sarcomas: A SEER population-based study and a literature review. RIS, SEER
54  2021 CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. DFCI, GA, ICI
55  2021 Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. CI, CIN, CTC, mCRPC, NE, OS, PH
56  2021 Complete Blood Count Score Model Predicts Inferior Prognosis in Primary Central Nervous System Lymphoma. CBCs, HR, NLR, OS, PCNSL, PFS, PLR, SII, SIRI
57  2021 Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC). C-index, CN, IMDC, mRCC, OM, REMARCC
58  2021 Differential Expression of a Panel of Ten CNTN1-Associated Genes during Prostate Cancer Progression and the Predictive Properties of the Panel Towards Prostate Cancer Relapse. CI, CNTN1, CRPC, HR, LE, PC
59  2021 Discharge prescribing of enteral opioids in opioid naive patients following non-surgical intensive care: A retrospective cohort study. EMR, LOS
60  2021 Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy. EGFR, NSCLC
61  2021 EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers. CNA, EPHA7-MUT, EPHA7-WT, ICIs, TMB, WES
62  2021 External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study. AUC, ePLND, PCa, PET, PSMA, RARP
63  2021 External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging. AUC, CI, DRE, ePLND, LNI, mpMRI, T stage
64  2021 Fifteen-MiRNA-Based Signature Is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients. RFS
65  2021 Gene Mutation Classification through Text Evidence Facilitating Cancer Tumour Detection. LR, NLP, RF, RNN, XGB
66  2021 Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas. ATCs, PDTCs, PTC
67  2021 Head-to-Head Comparison of Two Nomograms Predicting Probability of Lymph Node Invasion in Prostate Cancer and the Therapeutic Impact of Higher Nomogram Threshold. AUC, DCA, LNI, PCa, PLND, RP
68  2021 Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration. DDR, HR, ICIs, NAL, OS, TMB
69  2021 Integration of clinicopathologic identification and deep transferrable image feature representation improves predictions of lymph node metastasis in prostate cancer. AUCs, ePLND, PCa, PLNM
70  2021 Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort. DDR, ICB
71  2021 Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma. FDA, GM-CSF, HR-NBL
72  2021 Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room. AUC, ED, LOSETD, UCC
73  2021 Pathology Informatics Education during the COVID-19 Pandemic at Memorial Sloan Kettering Cancer Center (MSKCC). ---
74  2021 Predicting survival in colorectal carcinoma after curative resection: a new prognostic nomogram. AUC, C-index, CRC, MMRd, ROC
75  2021 Prediction of R0/R+ surgery by different classifications for locally recurrent rectal cancer. LRRC, NCIM
76  2021 Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy. ICI
77  2021 Preoperative ultrasound-based radiomics score can improve the accuracy of the Memorial Sloan Kettering Cancer Center nomogram for predicting sentinel lymph node metastasis in breast cancer. AUC, DCA, LASSO, mRMR, ROC, ROIs, SLN, US
78  2021 Prognosis and Genomic Landscape of Liver Metastasis in Patients With Breast Cancer. BCLM, DFS, KPS, LM, OS, PBC, PFS, SCHI
79  2021 Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era. IMDC, JMRC
80  2021 Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma: Model development and external validation with Memorial Sloan Kettering Cancer Center model and the international metastatic renal cell carcinoma database consortium model. AIC, IMDC, KRoCS, mRCC
81  2021 Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy. Hb, HD-MTX, LMR, NLR, OS, PCNSL, PFS, SII, TBIL
82  2021 Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma. IC, OS, PD-L1, PSW, RCC
83  2021 Prostate Magnetic Resonance Imaging Analyses, Clinical Parameters, and Preoperative Nomograms in the Prediction of Extraprostatic Extension. AUC, EPE, mpMRI, OR, PCa, RP
84  2021 Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. EFS, mCR
85  2021 Real-life drug-drug and herb-drug interactions in outpatients taking oral anticancer drugs: comparison with databases. CAM, DDI, HDI
86  2021 Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry. IMDC
87  2021 Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. BORs, irAEs, OS, TTF
88  2021 The Cost of Enfortumab Vedotin Wastage Due to Vial Size-A Real-World Analysis. EV
89  2021 The Effect of Anastomotic Leakage on the Incidence and Severity of Low Anterior Resection Syndrome in Patients Undergoing Proctectomy: A Propensity Score Matching Analysis. AL, LARS
90  2021 The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. GEO, HR, ICIs, NSCLC
91  2021 The Relationship Between Food Consumption and Bowel Symptoms Among Patients With Rectal Cancer After Sphincter-Saving Surgery. ---
92  2021 Treatment of Ductal Carcinoma in Situ: Considerations for Tailoring Therapy in the Contemporary Era. BCS, DCIS, LR
93  2021 [Impact of surgical treatment for locally recurrent rectal cancer on the quality of life of patients]. FSFI, IIEF-5, IPSS, LRRC, SF-36
94  2020 A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma. IELSG, NB, OS, PCNSL, PFS
95  2020 A novel miRNA inhibits metastasis of prostate cancer via decreasing CREBBP-mediated histone acetylation. ---
96  2020 Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer. HNSC, ICIs, MSI, MT, OS, TMB, WT
97  2020 Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer. CRC, ICIs, MT, OS
98  2020 Bevacizumab does not increase risk of perforation in patients undergoing percutaneous endoscopic gastrostomy or jejunostomy placement. GI, PEG, PEJ
99  2020 CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors. CCND1, DCs, ICIs, mTOR, PI3K, TGF, TME
100  2020 Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients. BC, CNAs, maxAF, PCAWG, TNBC